Targeted RNA-Seq of expression markers in NSCLC FFPE tumors requires integrated reagents, protocols, and interpretive software that can ensure consistent results across laboratories.
Download our poster to learn about this study, where a comprehensive targeted NGS system, the QuantideX® NGS RNA Lung Cancer Kit (RUO)*, was evaluated in 5 laboratories to assess accuracy and reproducibility.
Meet the Authors:
Victor Weigman, Ph.D., Director, Translational Genomics
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics
Tom Halsey
Dan Su
Maria Curtis
Complete the form below to access this scientific poster
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
